Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.

We tested the hypotheses that the glucagon response to hypoglycemia is reduced in patients who are approaching the insulin-deficient end of the spectrum of type 2 diabetes and that recent antecedent hypoglycemia shifts the glycemic thresholds for autonomic (including adrenomedullary epinephrine) and symptomatic responses to hypoglycemia to lower plasma glucose concentrations in type 2 diabetes. Hyperinsulinemic stepped hypoglycemic clamps (85, 75, 65, 55, and 45 mg/dl steps) were performed on two consecutive days, with an additional 2 h of hypoglycemia (50 mg/dl) in the afternoon of the first day, in 13 patients with type 2 diabetes---7 treated with oral hypoglycemic agents (OHA R(X); mean [+/- SD] HbA(1c) 8.6 +/- 1.1%) and 6 requiring therapy with insulin for an average of 5 years and with reduced C-peptide levels (insulin R(X), HbA(1c) 7.5 +/- 0.7%)---and 15 nondiabetic control subjects. The glucagon response to hypoglycemia was virtually absent (P = 0.0252) in the insulin-deficient type 2 diabetic patients (insulin R(X) mean [+/- SE] final values of 52 plus minus 16 vs. 93 plus minus 15 pg/ml in control subjects and 98 +/- 16 pg/ml in type 2 diabetic patients, OHA R(X) on day 1). Glucagon (P = 0.0015), epinephrine (P = 0.0002), and norepinephrine (P = 0.0138) responses and neurogenic (P = 0.0149) and neuroglycopenic (P = 0.0015) symptom responses to hypoglycemia were reduced on day 2 after hypoglycemia on day 1 in type 2 diabetic patients; these responses were not eliminated, but their glycemic thresholds were shifted to lower plasma glucose concentrations. In addition, the glycemic thresholds for these responses were at higher-than-normal plasma glucose concentrations (P = 0.0082, 0.0028, 0.0023, and 0.0182, respectively) at baseline (day 1) in OHA R(X) type 2 diabetic patients, with relatively poorly controlled diabetes. Because the glucagon response to falling plasma glucose levels is virtually absent and the glycemic thresholds for autonomic and symptomatic responses to hypoglycemia are shifted to lower glucose concentrations by recent antecedent hypoglycemia, patients with advanced type 2 diabetes, like those with type 1 diabetes, are at risk for hypoglycemia-associated autonomic failure and the resultant vicious cycle of recurrent iatrogenic hypoglycemia.

[1]  P. De Feo,et al.  Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM , 1994, Diabetologia.

[2]  I. Macdonald,et al.  Counterregulation in Type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis , 1987, Diabetologia.

[3]  A. Hattersley,et al.  Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes , 2000, The Lancet.

[4]  R. Holman,et al.  Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycemia? , 2000, Diabetes care.

[5]  G. Sundkvist,et al.  Random C-peptide in the classification of diabetes. , 2000, Scandinavian journal of clinical and laboratory investigation.

[6]  L. Kuller,et al.  Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. , 2000, Diabetes.

[7]  P. Cryer,et al.  Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. , 1998, Diabetes.

[8]  P. Cryer,et al.  Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. , 1998, Diabetes.

[9]  R. J. Hayes,et al.  United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy , 1998, Annals of Internal Medicine.

[10]  P. Cryer.  Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. , 1998, Advances in pharmacology.

[11]  R. Holman,et al.  UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes , 1997, The Lancet.

[12]  P. Cryer.  Hypoglycemia: Pathophysiology, Diagnosis, and Treatment , 1997 .

[13]  A. Giobbie-Hurder,et al.  Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. , 1996, JAMA.

[14]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[15]  F. Nuttall,et al.  Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial , 1995, Diabetes Care.

[16]  P. Cryer,et al.  Reversal of Hypoglycemia Unawareness, But Not Defective Glucose Counterregulation, in IDDM , 1994, Diabetes.

[17]  A. Maran,et al.  Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes , 1994, The Lancet.

[18]  D. Rogers,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .

[19]  H. Shamoon,et al.  Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. , 1994, The Journal of clinical investigation.

[20]  H. Tuokko,et al.  Counterregulatory Hormone Responses to Hypoglycemia in the Elderly Patient with Diabetes , 1994, Diabetes.

[21]  P. Cryer,et al.  Mechanism of Awareness of Hypoglycemia: Perception of Neurogenic (Predominantly Cholinergic) Rather Than Neuroglycopenic Symptoms , 1993, Diabetes.

[22]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[23]  B. Frier,et al.  Frequency and Symptoms of Hypoglycaemia Experienced by Patients with Type 2 Diabetes Treated with Insulin , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[24]  B. Frier,et al.  Frequency and Morbidity of Severe Hypoglycaemia in Insulin‐treated Diabetic Patients , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[25]  P. Cryer,et al.  Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. , 1993, The Journal of clinical investigation.

[26]  H. Shamoon,et al.  Counterregulatory adaptation to recurrent hypoglycemia in normal humans. , 1991, The Journal of clinical endocrinology and metabolism.

[27]  P. Reichard,et al.  Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years , 1991, Journal of internal medicine.

[28]  P. Cryer,et al.  Reduced Neuroendocrine and Symptomatic Responses to Subsequent Hypoglycemia After 1 Episode of Hypoglycemia in Nondiabetic Humans , 1991, Diabetes.

[29]  W. Tamborlane,et al.  Effect of Intensive Insulin Therapy on Glycemic Thresholds for Counterregulatory Hormone Release , 1988, Diabetes.

[30]  P. Cryer,et al.  Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. , 1988, The New England journal of medicine.

[31]  福田 正博.  Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control , 1988 .

[32]  P. Cryer,et al.  Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. , 1987, The Journal of clinical investigation.

[33]  H. Shamoon,et al.  Defective Epinephrine and Growth Hormone Responses in Type I Diabetes Are Stimulus Specific , 1987, Diabetes.

[34]  P. Cryer,et al.  External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. , 1985, The Journal of laboratory and clinical medicine.

[35]  P. Brunetti,et al.  A Reliable and Reproducible Test for Adequate Glucose Counterregulation in Type I Diabetes Mellitus , 1984, Diabetes.

[36]  P. Cryer,et al.  Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine intera , 1984, The Journal of clinical investigation.

[37]  M. Davidson.  Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. , 1984, The New England journal of medicine.

[38]  R. Hoeldtke,et al.  Counterregulatory Hormone Release and Glucose Recovery After Hypoglycemia in Non-insulin-dependent Diabetic Patients , 1983, Diabetes.

[39]  P. Cryer,et al.  Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. , 1983, The New England journal of medicine.

[40]  J. Ensinck,et al.  Immunoassays for Glucagon , 1983 .

[41]  R. Hoeldtke,et al.  Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones. , 1981, The New England journal of medicine.

[42]  D L Horwitz,et al.  Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics , 1977, Diabetes.

[43]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.